Inovio Pharmaceuticals is trading 5.25% lower at $1.53, with no verified company-specific announcement identified for November 5, 2026; the immediate driver remains unclear.
- The FDA approval of VOCERYQ was reported earlier and does not explain this morning’s decline.
- Third-quarter results are scheduled for November 10. Biotech ETF performance was positive in available premarket data, while the supplied market context showed the Nasdaq and S&P 500 lower.